Nanna Lüneborg, PhD

Dr. Nanna Lüneborg is currently a General Partner at Forbion. She focuses on late-stage investments from the Forbion Growth Opportunities Fund. Nanna is currently a member of the board of BioInvent (BINV) and has previously served on the boards of multiple privately held and publicly traded life science companies, including Lava Therapeutics (LVTX), Numab (private), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva Pharma (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private). Prior to her role at Forbion, she was with Apposite Capital and Novo Holdings, one of the largest global healthcare investors, where she was a key member of the European deal team focusing on late-stage biopharmaceutical investments across Europe. Nanna holds a PhD in neuroscience from University College London, an MBA from the University of Cambridge, and a BA in physiology and psychology from the University of Oxford.